Related Experiment Video

Updated: May 13, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Development of genomic markers that predict response to molecularly targeted antileukemic therapy

Mitch Raponi1, Jean-Luc Harousseau

  • 1Veridex, LLC, a Johnson & Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA +1 858 320 3319 ; +1 858 784 3182 ; mraponi1@ocdus.jnj.com.

Expert Opinion on Medical Diagnostics
|March 19, 2013
PubMed
Abstract

Insights

Identifying genomic biomarkers aids in predicting patient response to leukemia therapies. Integrating these assays with standard tests can improve antileukemic drug response prediction.

Area of Science:

  • Genomic medicine
  • Molecular oncology
  • Cancer genomics

Background:

  • Cancer genomes accumulate mutations, deregulating cell-signaling pathways.
  • Understanding these alterations enables targeted therapies and patient stratification.

Purpose of the Study:

  • To highlight progress in identifying genomic biomarkers for predicting antileukemic therapy response.
  • To discuss challenges in developing theranostic molecular assays.

Main Methods:

  • Focus on global gene expression profiling.
  • Utilized acute myeloid leukemia (AML) treated with tipifarnib as a case study.
  • Examined challenges in developing theranostic molecular assays.

Main Results:

  • Gene expression profiling can identify potential genomic biomarkers.
  • Tipifarnib treatment in AML demonstrated the application of these methods.
  • Development of theranostic assays faces specific challenges.

Conclusions:

  • Validated genomic assays are crucial for predicting drug response.
  • Combining genomic assays with morphological tests may enhance prediction accuracy.
  • This integration can lead to improved patient outcomes in leukemia treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...